Insulinoma epidemiology and demographics

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma epidemiology and demographics

CDC on Insulinoma epidemiology and demographics

Insulinoma epidemiology and demographics in the news

Blogs on Insulinoma epidemiology and demographics

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma epidemiology and demographics

Overview

Epidemiology and Demographics

Incidence

  • Insulinomas are rare neuroendocrine tumors with an incidence estimated at 1 to 4 new cases per million persons per year.
  • Insulinoma is one of the most common types of tumor arising from the islets of Langerhans cells (pancreatic endocrine tumors).
  • Estimates of malignancy (metastases) range from 5% to 30%.
  • Over 99% of insulinomas originate in the pancreas, with rare cases from ectopic pancreatic tissue.
  • About 5% of cases are associated with tumors of the parathyroid glands and the pituitary (Multiple endocrine neoplasia type 1) and are more likely to be multiple and malignant.
  • Most insulinomas are small, less than 2 cm.

Age

  • The median age at diagnosis is 45.5 years.[1]

Gender

  • Females are more commonly affected with insulinoma than males.[1]
  • The male to female ratio is approximately 2 to 3.

Race

  • There is no racial predilection to the insulinoma.

References

  1. 1.0 1.1 Vázquez Quintana E (2004). "The surgical management of insulinoma". Bol Asoc Med P R. 96 (1): 33–8. PMID 15575328.